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Abstract
Purpose of Review Osteoarthritis (OA) is a subset of joint disorders resulting in degeneration of synovial joints. This leads to
pain, disability and loss of independence. Knee and hip OA are extremely prevalent, and their occurrence increases with ageing.
Similarly, loss of muscle mass and function, sarcopenia, occurs during ageing.
Recent Findings Little is known about the impact of muscle wasting on OA progression; nevertheless, it has been suggested that
muscle wasting directly affects the stability of the joints and loss of mobility leads to gradual degeneration of articular cartilage.
The molecular mechanisms underlying muscle wasting in OA are not well understood; however, these are probably related to
changes in gene expression, as well as epigenetic modifications.
Summary It is becoming clear that skeletal muscle wasting plays an important role in OA development and/or progression. Here,
we discuss mechanisms, current interventions, such as exercise, and potentially novel approaches, such as modulation of
microRNAs, aiming at ameliorating OA symptoms through maintaining muscle mass and function.
Keywords Osteoarthritis . Muscle . Ageing . Exercise . microRNAs
Introduction
Osteoarthritis (OA) is a multifactorial condition associated
with degeneration of the joint, with pathological changes to
multiple musculoskeletal tissues such as cartilage, meniscus,
ligament and synovium. OA is characterised by degradation
of articular cartilage, subchondral bone sclerosis, the forma-
tion of osteophytes at the joint margin and synovitis [1].
Synovial inflammation (synovitis) has been demonstrated dur-
ing all stages of OA with synovium showing thickening and
inflammation even before visible cartilage degeneration [2]. In
addition, anterior cruciate ligament (ACL) injury, especially
with concomitant ligament or meniscal pathology, increases
the risk of knee OA suggesting an important role of healthy
ligaments in maintaining joint tissue homeostasis [3]. OA pa-
tients and rodent models of OA are characterised by changes
in cartilage, meniscus, synovium and ligament, suggesting
common mechanisms of joint degeneration during OA devel-
opment [1, 4]. Therefore, OA can be thought of as an organ
failure of the whole synovial joint. Linked to the joint, muscles
also play a major role in joint function during movement and
in joint stability, but this link has been seldom explored. In this
mini-review, we aim to provide current information linking
muscle wasting and OA.
Muscle Wasting in OA
The progressive loss of periarticular muscle mass and function
has consequences on joint stability and health.Muscle wasting
is inevitably associated with ageing, and, more recently, it has
been demonstrated in patients with OA [5–7]. The reduction
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in muscle mass and strength is attributed to myofibre atrophy,
reduction of muscle quality and defective muscle regeneration
(reviewed in [8]). Until recently, research investigating the
association of muscle wasting with OA has been lacking.
Currently, more and more data support the relationship be-
tween joint health and the surrounding skeletal muscle; how-
ever, functional and mechanistic studies are still lacking.
Muscle contractility is required for joint formation already
during embryogenesis [9], and muscle weakness is an impor-
tant determinant of pain and disability during OA [10].
Several studies have shown that a decrease in lower limb lean
mass is frequent in OA patients [11], and this is associated
with a greater risk of falls [12–14]. Progressive muscle weak-
ness in OA is also associated with muscle fibre atrophy, with
studies demonstrating 12–19% reduction in cross-sectional
area of muscles in patients with hip and knee OA [6].
Moreover, muscle damage is associated with articular carti-
lage degeneration [15], whereas the increased cross-sectional
area of vastus medialis is associated with improved structural
changes at the knee and reduced pain in OA patients [16].
On the other hand, a large longitudinal cohort study found
that, in 1653 subjects without radiographic knee OA (ROA) at
baseline, an increased risk of ROA was not associated with
sarcopenia alone, but rather with sarcopenic and body
composition–based obesity [17]. Though, it should be noted
that this study classified sarcopenia as the sum of absolute
muscle mass of upper and lower limbs. However, findings
from a previous study suggest that skeletal muscle mass of
the lower limbs shows a higher correlation with knee OA than
that of the lower and upper limbs combined [18]. Therefore, a
statistical association between the risk of knee OA and
sarcopenia may be observed, if the assessment of skeletal
muscle mass focuses on the lower limbs.
A study investigating the influence of pain and ROA on
muscle mass, strength, quality and risk of falls in older adults
showed that hip and knee ROA are not significantly associat-
ed with changes in muscle strength and quality, despite the
association of selfreported lower extremity joint pain, stiffness
and dysfunction with declines in the aforementioned muscle
parameters in older women. As such, it was concluded that
pain may be the underlying mechanism via which OA leads to
functional decline [19].
These contradictory results may be associated with a lack
of a clear definition of sarcopenia. In recent years, many def-
initions of sarcopenia have been proposed, each one
recommending diagnostic criteria based onmuscle mass com-
bined with measures of muscle strength, function or physical
performance [20]. It is therefore crucial that criteria for the
definition of sarcopenia are established and adopted in order
for research to obtain results that are clinically relevant.
Another limitation of research in this area is the lack of a
clear method to correlate the development of OA and inci-
dence of sarcopenia. The current method used by research to
investigate this relationship is to separately assess the OA
severity grade and the lean body mass (LBM) of the area of
interest [21]. Moreover, most of the research into OA and
sarcopenia focuses on whether or not there is a correlation
between the two disorders and has yet to fully investigate
the molecular mechanisms behind the observed changes. It
has been suggested that myokines, muscle-produced cyto-
kines, peptides and growth factors communicate with the sur-
rounding articular components such as the synovium, carti-
lage and bone through paracrine mediation, and thus may
affect the signalling cascades implicated in OA [22].
Of the studies exploring molecular mechanisms underlying
muscle wasting in OA, most have focused on inflammatory
mediators as the molecular link between muscle function and
OA. For example, Levinger et al. [23] observed increased
inflammation in the vastus lateralis in patients with knee
OA compared with a control group, based on increased pro-
tein abundance of p65 NF-κB, STAT-3 and JNK. However, a
recent study attempted to investigate changes in muscle qual-
ity in OA by conducting the first cellular-level analysis of the
vastus lateralis in adults with moderate knee OA [24]. Results
of this study showed significant pathogenic fibrosis in the
muscle of OA patients. Moreover, aberrant collagen deposi-
tion was noted in the extracellular matrix of OA muscle,
which was significantly associatedwith decreased satellite cell
density, as well as muscle strength. Increased expression
levels of both CCN2 and TGFβmRNAs were correlated pos-
itively to the amount of collagen deposition and inversely
correlated with muscle strength. Finally, results indicated a
muscle fibre type shift in the OA group, with significantly
more type IIa/x hybrid fibres and fewer type I fibres in OA
muscles relative to controls. Despite the limitations of this
study, including low sample sizes and its cross-sectional na-
ture, the data provide excellent molecular insight into the pa-
thology of muscle changes that occur during OA.
Nonetheless, there remains a large insufficiency of research
in this area, making it essential that future studies focus on
elucidating the mechanisms behind the influence of OA on
skeletal muscle in order to develop more targeted therapeutic
approaches. Interestingly, we have also shown that, in a spon-
taneous model of OA (STR/Ort mice), significant changes
occur in the expression of muscle-related genes in the articular
cartilage, suggesting at least some common molecular mech-
anisms underlying degeneration of musculoskeletal tissues
during OA [25].
Another question remains to be answered: whether muscle
changes precede OA, or vice versa. Studies have shown that
low muscle quality and the depletion of lean body mass of
lower extremities/body weight may be risk factors as impor-
tant a contributor to OA pathogenesis as mechanical influ-
ences [26]. On the other hand, it has been suggested that the
disuse of an OA affected joint, due to the pain of movement,
may be the primary cause of the reduction in muscle strength
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associatedwith OA [27]. To add to the complexity, data from a
study investigating muscle wasting in an anterior cruciate lig-
ament transection (ACLT) model of OA suggest that disuse
does not fully explain the muscle wasting observed in OA
patients [6]. Results of this research show that rats in the OA
group display the same pattern of movement as those of
SHAM group (i.e., rats submitted to surgery without
ALCT). Despite the similar locomotion (measured as sponta-
neous exploratory velocity and distance), the gastrocnemius
crosssectional area was reduced by approximately 10% in the
OA group. It was concluded, therefore, that muscle wasting
may be a consequence of chronic, low-grade inflammation
associated with OA, rather than solely joint disuse.
However, the authors did acknowledge that the rats in the
OA group displayed significantly increased nociception to-
wards the end of the study, suggesting that the extended ex-
perimental period could have allowed for the detection of
reduction in joint use.
The results of the above studies highlight the need to mon-
itor the tendency of OA patients to avoid physical activity. It
may prove beneficial for patients identified from this assess-
ment to undergo therapeutic exercise intervention as a means
to alleviate the symptoms of OA, as well as to improve their
muscle strength.
Exercise Interventions to Maintain Muscle
Mass and Function During OA
Current exercise interventions for OA focus highly on lifestyle
modification, weight reduction and specific exercise interven-
tions that focus on strengthening periarticular musculature [28,
29]. This is not without challenge, however, as many OA pa-
tients are unable to tolerate the load intensity required for pro-
gressive overloading of the relevant musculature [28].
Fortunately, the examination of modifications in low impact
exercise, such as swimming and cycling, has shown a beneficial
reduction in pain, stiffness and functional deficits in patients
with knee OA [29, 30]. In a 12-week study examining swim-
ming and cycling as exercise therapy for moderate knee OA,
patients from both groups showed increased distance achieved
in a 6minute walk test, as well as increased isokinetic knee
extensor and flexor strength. Additionally, in the swimming
cohort, there was an approximately 40% reduction in joint pain,
as assessed by the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) [29]. Limitations to this study,
however, were the lack of participation of patients with ad-
vanced OA and the short intervention time. Other areas of re-
search have evaluated similar low-load (2050% of one-
repetition maximum) exercise training in knee OA patients
utilising a partial vascular occlusion approach, wherein a pres-
sure cuff or tourniquet is applied to the upper thigh, with similar
results in pain reduction and functional improvements as
compared with the conventional strength-training group (i.e.,
70% of one-repetition maximum), yet with reduced knee pain
whilst exercising [28]. The assumption is that this technique
provides greater type II fibre activation via a generated anaero-
bic environment, whilst other possible mechanisms include in-
creased intracellular metabolites (e.g., H+ protons, lactate and
adenosine monophosphate), which in turn may stimulate
growth hormone secretion [28, 31].
The majority of the literature suggests that sedentary lifestyle
behaviours and immobilization are associated with cartilage dis-
ease and progression of OA, whereas controlled loading of the
knee is associated with favourable changes to the extracellular
matrix and molecular biomarkers associated with OA such as
Creactive protein and IL-10 [32]. Therapeutic exercise is bene-
ficial to cartilage health, as the literature suggests molecular
biomarkers associated with inflammation (i.e., CRP and
TNFα) and cartilage breakdown (C12C, CTX-II and COMP)
are either unchanged or downregulated in studies examining
these characteristics in exercise and OA [32]. Furthermore, ex-
ercise programmes focusing on neuromuscular control, such as
closed chain kinetic and proprioceptive exercises, are generally
well tolerated in OA patients and show results similar to more
traditional strengthening exercises [33, 34]. This is consistent
with literature suggesting that aberrations in the neuro-motor
system are involved in changes to muscle force patterns, with
altered joint reaction forces leading to focal alterations to carti-
lage loading over time [35]. This suggests that there is a complex
relationship between both muscular strength and changes to
motor unit physiology in OA, and strengthening alone may
not be the only consideration in clinical practice [35]. Meta-
analyses show that no specific protocol is deemed the best and
current guidelines are ambiguous in recommending exercise
programs [36]; thus, the best exercise programme may be the
one that is met with high adherence by the individual and toler-
ated enough to provide consistent progression over time with
graded adjustments to load and volume. Recent exercise inter-
ventions in OA patients are summarised in Table 1.
microRNAs as Novel Therapeutic Targets
for Muscle Wasting During OA
MicroRNAs (also referred to as miRNAs or miRs) are a class
of small non-coding RNA molecules, approximately 22 nu-
cleotides long, which bind to their target messenger RNAs
(mRNAs), induce mRNA degradation or inhibit protein trans-
lation, and thus exert post-transcriptional regulation of gene
expression [38]. Studies report that specific miRNA-target
interactions may regulate all major known contributors to
the onset of the senescent phenotype, such as DNA damage,
telomere shortening, protein misfolding and oxidative stress
[39]. Therefore, recent research has focused on investigating
whether restoring physiologic levels of specific miRNAs in
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these tissues can restore—at least partially—functional ho-
meostasis [40]. Investigating the use of miRNA therapies in
disorders such as OA is particularly important given that the
only current treatment options for the condition are pain and
symptommanagement and eventual joint replacement therapy
[41]. It is anticipated that elucidating the underlyingmolecular
mechanisms of the disorder, in particular the associated genet-
ic and epigenetic dysregulation, will lead to the development
of novel interventions to delay the need for invasive and tran-
sient total joint replacement procedures.
One of the most well-studied miRNAs in OA research,
to date, is miR-140, a cartilage-specific miRNA [42],
which was first implicated in OA pathogenesis in a study
by Miyaki et al. This study showed that miR-140 expres-
sion in articular cartilage from OA donors is significantly
lower than that in normal cartilage or following treatment
with IL-1β, a cytokine known to be involved in the path-
ogenesis of OA. Interestingly, the transfection of
chondrocytes with miR-140 downregulated IL-1β-
induced ADAMTS5 gene expression. The correlation of
abnormal miR-140 expression in OA cartilage with in-
creased ADAMTS5, as first reported in this study [42],
suggests that miR-140 may play an important role in main-
taining cartilage homeostasis. Since then, multiple studies
have shown that miRNAs play significant roles in cartilage
homeostasis. Moreover, there is evidence that miRNAs are
important players in maintaining the health of all joint tis-
sues, including muscle [43–47], cartilage [48, 49] and lig-
ament and tendon [50, 51]. Whilst there is very little
known about the role of specific microRNAs in muscle
wasting during OA, with only one microRNA, miR-141,
suggested to have a function in the ageing of the multiple
tissues of the musculoskeletal system [52], multiple studies
have shown the involvement of miRNAs in muscle
wasting [53–55]. The importance of microRNAs in the
function of musculoskeletal tissues was also demonstrated
in depletion studies of Dicer, a key enzyme in miRNA
biogenesis. The deletion of Dicer in chondrocytes resulted
in defective cell proliferation and differentiation [51], and
the deletion of Dicer in bone progenitors was associated
with defective bone formation [56]. A satellite cell–
specific Dicer knockout resulted in mild muscle fibre atro-
phy over time [57], and microRNAs maintain muscle ho-
meostasis through the control of muscle hypertrophy and
atrophy and muscle adaptation to exercise [58–60]. Below,
we focus on several examples of microRNAs with a poten-
tial role in regulating homeostasis of muscle and other joint
tissues in the context of OA.
Table 1 Summary of research examining effects of exercise on muscle during osteoarthritis
Exercise type Sex Effects References
Moderate intensity
(60% of one-repetition maximum)
resistance exercise
Males and females with knee OA •Increased quadriceps CSA ~ 7%
• No change in single- muscle fibre CSA
• Increased intermyofibrillar mitochondrial size in men
• Improved one-repetition maximum strength
• Improved contractility in men
• Minimal effects to improve muscle atrophy
[35]
Neuromuscular exercise or
quadriceps strengthening
Males and females with knee OA • Both neuromuscular exercise (NEMEX) and quadriceps
strengthening groups showed improvements in pain
and function
• No observed differences were seen between either NEMEX
or quadriceps-specific strengthening with respect to
strength improvements
[33]
Resistance training with partial
vascular occlusion (PVO)
(30% of one- repetition maximum)
Females with knee OA • Reduced anterior knee pain with PVO compared with
conventional loads (70% one-repetition maximum)
• Both PVO and conventional load groups showed
improvements in quadriceps strength, function and pain
[28]
Resistance based circuit training Males and Females with knee OA • Increased walking speed
• Reduction in pain
• Increased strength of knee flexors and extensors
• Increased isometric strength of hip abductors
[30]
Non-weight bearing resistance
exercise (swimming/cycling)
Females with knee OA • All groups reported reductions in pain, joint stiffness and
physical limitation
• Increased function assessed by hand grip, knee extension
and flexion power and increased distance in 6-min walk test
• Do differences observed between groups
(swimming vs cycling)
[29]
Aerobics/step- aerobics Females with knee OA • Improved cartilage quality
• 11% greater isometric knee extension force compared
with control
• No difference in self-rated knee OA symptoms
[37]
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miR-143 is differentially expressed in the cartilage of older
people suffering from OA [53]. Interestingly, miR-143 regu-
lates the phenotype of synovial fibroblasts in rheumatoid ar-
thritis through the regulation of IGFBP5 [61]. Our group has
previously demonstrated the regulation of senescence of sat-
ellite cells, adult skeletal muscle stem cells, via the miR-
143:Igfbp5 regulatory network [47]. Interestingly,
miR-143:Igfbp5 interactions are regulated by inflammatory
cytokines, including IL6.
Our group has also shown that miR-181 is downregulated
in muscle during ageing and regulates the expression of Sirt1
[46]. Interestingly, another group has shown that the expres-
sion of miR-181 is also altered in the joints of OA patients and
that inhibition of this microRNA in animal models of OA
attenuates OA in facet and knee joints [62].
Another microRNA downregulated in muscle of humans
during ageing is miR-378 [63], which controls myogenesis,
metabolism and autophagy [55, 64, 65]. Indeed, molecules
regulating miR-378 have been patented for the use in regulat-
ing metabolism in different tissues, including skeletal muscle
(patent number WO2011153542A3). The changes in the reg-
ulation of cellular metabolism, for example through autopha-
gy, have also been noted during OA, and miR-378 has been
detected in synovium in late-stage OA patients [66, 67].
Moreover, miR-378 promotes osteogenesis in human bone
marrow–derived mesenchymal stem cells, suggesting that it
is a pro-bone regeneration molecule [68]. Together, these data
indicate a potential common mechanism, via miR-378 and
other microRNAs, underlying musculoskeletal tissues
homeostasis.
Whilst multiple studies have focused on the role of
microRNAs in muscle development and regeneration, very
few functional studies exist that have characterised the role of
microRNAs in muscle wasting during ageing or OA [69, 70].
It also has to be noted that Soares et al. [45] demonstrated
that microRNA function is context dependent in different
models of muscle atrophy; therefore, a question arises whether
the miR-associated mechanisms of muscle wasting during
ageing are similar or different to those observed duringmuscle
wasting in OA. Functional studies of microRNAs in muscle
during OA are needed.
Conclusions
OA is a progressive and debilitating disease and the most
common cause of chronic disability in adults. Despite
this, pain management and total joint replacement proce-
dures are the only current treatment options for the dis-
ease. As such, a lot of research into OA has focused on
the development of novel interventions to delay the need
for invasive total joint replacement procedures. The asso-
ciation between skeletal muscle mass and function and
OA development and progression remains to be elucidat-
ed; however, it is becoming clearer that changes in skel-
etal muscle are important players in OA. As such, exer-
cise interventions could benefit OA patients not only due
to benefits on muscle tissues, but also through all joint
tissues affected by OA. An emerging approach to inter-
ventions against OA includes the regulation of expression
and function of microRNAs. Although the role of
microRNAs in muscle wasting in OA is not yet under-
stood, given that a single microRNA can regulate multiple
genes and dysregulation of microRNA expression occurs
in a variety of pathological conditions, microRNAs are
emerging powerful regulatory molecules and potential
novel therapeutic agents; indeed, microRNAbased thera-
pies are currently undergoing clinical trials [71].
Though currently in its infancy, the use of miRNA-based
therapeutics in OA, including but not limited to regulating
muscle mass and function, is a promising avenue of research,
with many recent studies suggesting that their use may over-
come the limitations of many traditional therapies. However,
functional approaches are lacking. Moreover, experiments
using more relevant animal OA models and large-scale or
cohort-based clinical trials should be conducted in order to
comprehensively evaluate the efficacy of miRNA therapeutics
in OA.
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